Ocugen, Inc. Announces Completion of Dosing in Subjects with Geographic Atrophy Secondary to dAMD in High-Dose Cohort of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Novel Modifier Gene Therapy
25 juil. 2024 06h30 HE
|
Ocugen
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering,...
Emerging Gene Therapies Signal Transformative Shift in Retinal Disorder Treatment, According to Spherix Global Insights
24 juil. 2024 09h56 HE
|
Spherix Global Insights
EXTON, PA., June 20, 2024, July 24, 2024 (GLOBE NEWSWIRE) -- The American Society of Retinal Specialists (ASRS) annual meeting held last week in Stockholm, Sweden, showcased groundbreaking...
Gene Therapies For Cardiomyopathies Therapeutics Market Report 2024: Current Treatment Patterns, Clinical Assessment of Products, Pipeline Development Activities
18 juil. 2024 07h16 HE
|
Research and Markets
Dublin, July 18, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapies For Cardiomyopathies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.Gene Therapies For...
Gene Therapy Agreements Analysis Report and Directory 2024: Comprehensive Listing of 740 Deals Announced Since 2016
17 juil. 2024 05h31 HE
|
Research and Markets
Dublin, July 17, 2024 (GLOBE NEWSWIRE) -- The "Gene Therapy Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Gene Therapy Collaboration and...
California Institute for Regenerative Medicine (CIRM) Appoints New CEO
10 juil. 2024 15h30 HE
|
California Institute for Regenerative Medicine (CIRM)
South San Francisco, California, July 10, 2024 (GLOBE NEWSWIRE) -- The Independent Citizens’ Oversight Committee (ICOC), the governing board of the California Institute for Regenerative Medicine...
Neha Motwani Elected to Longeveron® Board of Directors
09 juil. 2024 09h00 HE
|
Longeveron
Neha Motwani, a senior healthcare investment banker, has been elected to the Longeveron Board of Directors
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease
09 juil. 2024 07h05 HE
|
uniQure Inc.
~ Achieved statistically significant, dose-dependent, and durable evidence of potential therapeutic benefit; Patients receiving high-dose AMT-130 showed 80% slowing of disease progression in the...
Gene Therapy Pioneer Roger Hajjar, MD, Elected to Longeveron® Board of Directors
08 juil. 2024 09h00 HE
|
Longeveron
Gene therapy pioneer Dr. Roger Hajjar elected to Longeveron Board of Directors as company advances it novel cellular therapy across multiple indications.
Viral Vector Manufacturing Industry Research 2024
03 juil. 2024 10h26 HE
|
Research and Markets
Dublin, July 03, 2024 (GLOBE NEWSWIRE) -- The "Viral Vector Manufacturing Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
02 juil. 2024 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...